Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study

In a randomized, evaluator-blind, multicenter trial, we compared cefepime (2 g three times a day) with imipenem-cilastatin (500 mg four times a day) for the treatment of nosocomial pneumonia in 281 intensive care unit patients from 13 centers in six European countries. Of 209 patients eligible for p...

Täydet tiedot

Bibliografiset tiedot

Julkaisussa:	Antimicrob Agents Chemother
Päätekijät:	Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., Romand, J.-A., Bille, J., Aymon, D., Stratchounski, L., Krawczyk, L., Rubinstein, E., Schaller, M.-D., Chiolero, R., Glauser, M.-P., Cometta, A.
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	American Society for Microbiology (ASM) 2003
Aiheet:	Clinical Therapeutics
Linkit:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC253800/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14576100/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.11.3442-3447.2003
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!